

Anti-TIGIT / VSIG9 / VSTM3 Reference Antibody (Tamgiblimab)

Catalog # APR11256

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q495A1
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4SP-FLAA-noK
Calculated MW	26319

Additional Information


Target/Specificity	TIGIT / VSIG9 / VSTM3
Expression system	CHO

Protein Information


Name	TIGIT
Synonyms	VSIG9, VSTM3
Function	Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells (PubMed: 19011627). Upon binding to its ligands PVR/CD155 or NECTIN2/CD112, which are expressed on antigen-presenting cells, sends inhibitory signals to the T-cell or NK cell. Mechanistically, interaction with ligand leads to phosphorylation of the cytoplasmic tail by Src family tyrosine kinases such as FYN or LCK, allowing subsequent binding to adapter GRB2 and SHIP1/INPP5D. In turn, inhibits PI3K and MAPK signaling cascades (PubMed: 23154388). In addition, associates with beta-arrestin-2/ARRB2 to recruit SHIP1/INPP5D that suppresses autoubiquitination of TRAF6 and subsequently inhibits NF- kappa-B signaling pathway (PubMed: 24817116). Also acts as a receptor for NECTIN4 to inhibit NK cell cytotoxicity (PubMed: 32503945).
Cellular Location	Cell membrane; Single-pass type I membrane protein. Note=Clustered to the immunological synapse where it disrupts granule polarization and cytotoxicity of NK cells once engaged with PVR.
Tissue Location	Expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level)



Anti-TIGIT / VSIG9 / VSTM3 Reference Antibody (Tamgiblimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-TIGIT / VSIG9 / VSTM3 Reference Antibody (Tamgiblimab) is 100%, determined by SEC-HPLC.



Immobilized hTIGIT.his at 2 µg/mL can bind Tamgiblimab, EC50= 0.01628 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.